Myeloid Cell-Targeted miR-146a Mimic Inhibits NF-kB-Driven Inflammation and Leukemia Progression in Vivo.
暂无分享,去创建一个
D. Baltimore | M. Kortylewski | G. Marcucci | Xiuli Wang | M. Boldin | P. Swiderski | S. Forman | Yu-Lin Su | Mati Mann | Tomasz Adamus | Dongfang Wang | D. Moreira | Zhuoran Zhang | C. Ouyang | Xin He | Bin Zhang | Ling Li
[1] Ryan L Setten,et al. The current state and future directions of RNAi-based therapeutics , 2019, Nature Reviews Drug Discovery.
[2] Aaron J Johnson,et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. , 2019, Blood.
[3] M. Kortylewski,et al. Targeted Delivery of miRNA Antagonists to Myeloid Cells In Vitro and In Vivo. , 2019, Methods in molecular biology.
[4] D. Ann,et al. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype , 2019, Cancer Immunology Research.
[5] M. Gantier,et al. A guide to miRNAs in inflammation and innate immune responses , 2018, The FEBS journal.
[6] S. Rose-John,et al. Control of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells , 2018, PloS one.
[7] Aly A. Khan,et al. Differential cell-intrinsic regulations of germinal center B and T cells by miR-146a and miR-146b , 2018, Nature Communications.
[8] S. Dowdy,et al. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. , 2018, Nucleic acid therapeutics.
[9] S. Ghosh,et al. Induction of innate immune memory via microRNA targeting of chromatin remodeling factors , 2018, Nature.
[10] M. Sadelain,et al. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.
[11] C. Doglioni,et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.
[12] H. Wong,et al. Nuclear PTEN enhances the maturation of a microRNA regulon to limit MyD88-dependent susceptibility to sepsis , 2018, Science Signaling.
[13] J. Lieberman. Tapping the RNA world for therapeutics , 2018, Nature Structural & Molecular Biology.
[14] Mithat Gonen,et al. Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[15] Yate-Ching Yuan,et al. Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia , 2018, Nature Medicine.
[16] P. Hwu,et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.
[17] A. Rudensky,et al. An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses , 2017, Nature Communications.
[18] Ryan M. O’Connell,et al. MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts. , 2017, Blood.
[19] Takashi Sato,et al. Class A CpG Oligonucleotide Priming Rescues Mice from Septic Shock via Activation of Platelet-Activating Factor Acetylhydrolase , 2017, Front. Immunol..
[20] J. Inoue,et al. miR-146a–Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression , 2017, Proceedings of the National Academy of Sciences.
[21] P. Low,et al. FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer , 2017, Science Translational Medicine.
[22] P. Cicuta,et al. Lipopolysaccharide-induced NF-κB nuclear translocation is primarily dependent on MyD88, but TNFα expression requires TRIF and MyD88 , 2017, Scientific Reports.
[23] F. Slack,et al. Targeting noncoding RNAs in disease , 2017, The Journal of clinical investigation.
[24] F. Slack,et al. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases , 2017, Nature Reviews Drug Discovery.
[25] A. Brenner,et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors , 2017, Investigational New Drugs.
[26] Christine E Brown,et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.
[27] D. Baltimore,et al. MicroRNAs as regulatory elements in immune system logic , 2016, Nature Reviews Immunology.
[28] Q. Cai,et al. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. , 2016, Blood.
[29] Jianbiao Zhou,et al. Aberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target , 2015, Oncotarget.
[30] Christopher J. Cheng,et al. MicroRNA silencing for cancer therapy targeted to the tumor microenvironment , 2014, Nature.
[31] Leaf Huang,et al. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. , 2015, Advanced drug delivery reviews.
[32] D. Tenen,et al. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia , 2014, Leukemia.
[33] M. Fabbri,et al. MicroRNAs and other non-coding RNAs as targets for anticancer drug development , 2013, Nature Reviews Drug Discovery.
[34] Xiuli Wang,et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. , 2013, Blood.
[35] K. Sliwa,et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. , 2013, The Journal of clinical investigation.
[36] Hua Yu,et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. , 2013, Blood.
[37] Ryan M. O’Connell,et al. microRNA regulation of inflammatory responses. , 2012, Annual review of immunology.
[38] David Baltimore,et al. MicroRNAs, new effectors and regulators of NF‐κB , 2012, Immunological reviews.
[39] F. Slack,et al. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy , 2011, Nature Reviews Cancer.
[40] P. Linsley,et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice , 2011, The Journal of experimental medicine.
[41] Ryan M. O’Connell,et al. NF-κB dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies , 2011, Proceedings of the National Academy of Sciences.
[42] Ryan D. Morin,et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. , 2009, Blood.
[43] C. Croce,et al. Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.
[44] Ryan D. Morin,et al. Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype , 2010, Nature Medicine.
[45] Hua Yu,et al. TLR agonist–Stat3 siRNA conjugates: cell-specific gene silencing and enhanced antitumor immune responses , 2009, Nature biotechnology.
[46] George A. Calin,et al. MicroRNAs — the micro steering wheel of tumour metastases , 2009, Nature Reviews Cancer.
[47] A. Krieg,et al. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. , 2009, Advanced drug delivery reviews.
[48] D. Baltimore,et al. MicroRNAs and immunity: tiny players in a big field. , 2007, Immunity.
[49] K. Ishii,et al. Human Peripheral Blood Cells Differentially Recognize and Respond to Two Distinct CpG Motifs1 2 , 2001, The Journal of Immunology.